HHS Recovery Act Recipient Reporting Readiness Tool

Step 4. Review and Copy the Grant Awards Data

TAGGS provides some – but not all – of the data needed for the Recipient Report. Recipients are responsible for directly collecting and reporting all required data to FederalReporting.gov. Data that HHS does not currently collect are highlighted in yellow. Do not copy this highlighted information. Please enter the appropriate data for your organization in these required fields. For assistance with entering these data please contact FederalReporting.gov.

You may capture the data HHS does provide by copying data from this screen and pasting it into the reporting format of your choice, such as the Excel spreadsheet template, the XML template, or by logging into the online form. For assistance with copying and pasting these data please email our help desk at Readiness Help

Prime Recipient Report

Award Detail for: ROLE OF GANGLIOSIDES IN TUMOR PROGRESSION
Recipient Name:CHILDREN'S RESEARCH INSTITUTE
DUNS Number: 143983562
111 MICHIGAN AVENUE, NW
WASHINGTON, DC 20010-2978

Reporting Information

Award Type*: Grant

Award Number*: 5R01CA061010-15

Final Report*: Recipient responsible for this data

Award Recipient Information

Recipient DUNS Number*: 143983562

Recipient Account Number: Recipient responsible for this data

Recipient Congressional District*: Not Available

Award Information

Funding Agency Code*: 7529

Awarding Agency Code*:7529

Award Date*: 06-25-2010

Amount of Award*: $ 384,052

Program Source (TAS)*: 750850

CFDA Number*: 93.701

Sub Account Number for Program Source (TAS)*: Recipient responsible for this data

Total Number of Sub Awards to Individuals*: Recipient responsible for this data

Total Amount of Sub Awards to Individuals*: Recipient responsible for this data

Total Number of Payments to Vendors less than $25,000/award*: Recipient responsible for this data

Total Amount of Payments to Vendors less than $25,000/award*: Recipient responsible for this data

Total Number of Sub Awards less than $25,000/award*: Recipient responsible for this data

Total Amount of Sub Awards less than $25,000/award*: Recipient responsible for this data

Award Description* DESCRIPTION (provided by applicant): Tumor progression, and particularly that of some neuroectodermal tumors (e.g., neuroblastoma and melanoma) causes most cancer-related morbidity and mortality. Thus, understanding and preventing progression is critical to developing effective cancer therapies. The synthesis and shedding of the membrane glycosphingolipids, gangliosides, has been strongly implicated by our past findings and the work of others in contributing to processes that facilitate tumor progression. Moreover, we have made significant progress in elucidating basic mechanisms in vitro by which gangliosides modulate the behavior of host cells found in the tumor microenvironment. We obtained clear evidence for the impact of ganglioside synthesis and shedding on cell signaling and on angiogenic responses of human endothelial cells, and found that pharmacological inhibition of glycosphingolipid synthesis has a striking inhibitory effect upon tumor growth. Based on these findings we hypothesize that gangliosides enhance tumor progression in vivo, and that interference with the synthesis of tumor gangliosides will impede tumor progression in vivo. However, an adequate animal model system of specific and constitutive inhibition of ganglioside synthesis in vivo has been lacking, and here we propose to fill this gap, by studying tumor progression in two different and complementary novel animal model systems that we are creating. In aim 1 we will develop two oncogene transformed ganglioside-deficient fibroblast tumor cell lines, one by GM3synthase/GM2synthase double knockout and the other by 4-OH-tamoxifen-inducible, cre-mediated deletion of glucosylceramide synthase (GCS). In aim 2 we will develop a unique ganglioside-depleted rodent tumor model by cre-mediated excision of the GCS gene in an orthotopic neuroectodermal (transgenic melanoma) tumor system in vivo. In Aim 3 we will comprehensively determine how ganglioside knockout in these ganglioside-depleted tumor systems affects tumor progression, providing the first unambiguous insights in vivo in a genetically controlled and stable system. Accomplishment of these aims will begin to elucidate the role and basic mechanisms by which gangliosides modulate tumor progression in vivo. This knowledge will lead to our ultimate goals of full delineation of the biological activity of tumor gangliosides in tumor progression and the development of novel therapeutic approaches to human cancer built upon this knowledge. PUBLIC HEALTH RELEVANCE: Understanding and prevention of tumor progression is critical for development of effective cancer therapies. The goal of the research proposed in this application is to determine exactly how production and shedding by tumor cells of a special type of lipids, named gangliosides, helps tumors to grow. The results of our studies will potentially allow modulation of ganglioside production/activity by tumors, which will in turn enable design of novel and effective treatments of cancer patients.

Project Information

Project Name or Project/Program Title*: ROLE OF GANGLIOSIDES IN TUMOR PROGRESSION

Project Status*: Recipient responsible for this data

Total Federal Amount of ARRA Funds Received/Invoiced*: Recipient responsible for this data

Number of Jobs*: Recipient responsible for this data

Description of Jobs Created*: Recipient responsible for this data

Quarterly Activities/Project Description*: Recipient responsible for this data

Activity Code (NAICS or NTEE-NPC)*: Recipient responsible for this data

Total Federal Amount of ARRA Expenditure* (Enter the cumulative total amount of Recovery Funds received that were expended to projects or activities. Refer to the Data Model for details on how to calculate this amount.): Recipient responsible for this data

Total Federal ARRA Infrastructure Expenditure Recipient responsible for this data

Infrastructure Contact Name: Recipient responsible for this data

Infrastructure Contact Email: Recipient responsible for this data

Infrastructure Contact Phone: Recipient responsible for this data

Infrastructure Contact Phone Ext: Recipient responsible for this data

Infrastructure Contact Street Address 1: 111 MICHIGAN AVENUE, NW

Infrastructure Contact Street Address 2: Not Available

Infrastructure Contact Street Address 3: Recipient responsible for this data

Infrastructure City: WASHINGTON

Infrastructure State: DC

Infrastructure ZIP Code+4: 20010-2978

Infrastructure Purpose and Rationale (If applicable, enter an explanation about how the infrastructure investment will contribute to one or more purposes of the Recovery Act. Refer to the Data Model for details on what to report. 4000 characters or less.): Recipient responsible for this data

Primary Place of Performance

Street Address 1: 111 MICHIGAN AVENUE NW

Street Address 2: WASHINGTON

City*: WASHINGTON

State*: DC

ZIP Code+4*: 20010

Congressional District*: 98

Country*: US

Recipient Highly Compensated Officers

Prime Recipient Indication of Reporting Applicability*: Recipient responsible for this data

1. Officer Name and Compensation: Recipient responsible for this data
2. Officer Name and Compensation: Recipient responsible for this data
3. Officer Name and Compensation: Recipient responsible for this data
4. Officer Name and Compensation: Recipient responsible for this data
5. Officer Name and Compensation: Recipient responsible for this data

This concludes the current search. To begin a new search, return to the HHS Recovery Act Recipient Reporting Readiness Tool Landing Page.